Drug Profile

ADO 12

Alternative Names: ADO-12; AdoShell® Islets; Cell therapy for diabetes - Adocia; Pancreatic beta cell therapy - Adocia

Latest Information Update: 31 Jul 2026

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Adocia
Class Antihyperglycaemics; Cell therapies; Stem cell therapies
Mechanism of Action Pancreatic beta cell replacements

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No
Available For Licensing Yes

Highest Development Phases

Suspended Type 1 diabetes mellitus

Most Recent Events

12 May 2026 Suspended - Preclinical for Type 1 diabetes mellitus in France (Parenteral)
15 Oct 2025 Preclinical development in Type-1 diabetes mellitus is ongoing in France (Parenteral) (Adocia pipeline, October 2025)
15 Oct 2025 Adocia plans to submit a clinical trial application for AdoShell® with human islets in Q3 2026

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com